Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease (STEADY-PD)

This study has been completed.
Sponsor:
Collaborators:
Michael J. Fox Foundation for Parkinson's Research
Northwestern University Dixon Fund
The Parkinson Study Group
Information provided by (Responsible Party):
Tanya Simuni, Northwestern University
ClinicalTrials.gov Identifier:
NCT00909545
First received: May 26, 2009
Last updated: April 16, 2013
Last verified: April 2013
  Purpose

The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.


Condition Intervention Phase
Parkinson Disease
Drug: Isradipine CR 5mg
Drug: Isradipine CR 10mg
Drug: Isradipine CR 20mg
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR. [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group.


Secondary Outcome Measures:
  • Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS) [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.

  • Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability.

  • Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability

  • Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability.

  • Efficacy: Change in Modified Hoehn & Yahr Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability.

  • Efficacy: Change in Modified Schwab & England Independence Scale [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability).

  • Efficacy: Change in Beck Depression Inventory II (BDI-II) [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.

  • Efficacy: Change in Montreal Cognitive Assessment [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.

  • Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39) [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: No ]
    The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability.

  • Vital Signs: Change in Systolic Standing [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
  • Vital Signs: Change in Systolic Supine [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
  • Vital Signs: Change in Diastolic Standing [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
  • Vital Signs: Change in Diastolic Supine [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
  • Vital Signs: Change in Pulse Standing [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
  • Vital Signs: Change in Pulse Supine [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
  • Common Adverse Events: Oedema Peripheral [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects.

  • Common Adverse Events: Dizziness [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Nasopharyngitis [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Headache [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Constipation [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Fatigue [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Nausea [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Upper Respiratory Tract Infection [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Depression [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Somnolence [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Insomnia [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Dyspepsia [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Diarrhoea [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Sinusitis [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Back Pain [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.

  • Common Adverse Events: Hypotension [ Time Frame: Baseline to 12 months or the time to require dopaminergic therapy ] [ Designated as safety issue: Yes ]
    Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.


Enrollment: 99
Study Start Date: July 2009
Study Completion Date: February 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Isradipine CR 5mg
Isradipine CR 5mg/day
Drug: Isradipine CR 5mg
5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
Other Names:
  • Isradipine CR
  • Dynacirc CR
Active Comparator: Isradipine CR 10mg
Isradipine CR 10mg/day
Drug: Isradipine CR 10mg
10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
Other Names:
  • Isradipine CR
  • Dynacirc CR
Active Comparator: Isradipine CR 20mg
Isradipine CR 20mg/day
Drug: Isradipine CR 20mg
20mg dose: 4 Dynacirc CR 5mg tablets once daily
Other Names:
  • Isradipine CR
  • Dynacirc CR
Placebo Comparator: Placebo
Placebo
Drug: Placebo
4 Placebo to Match (PTM) tablets once daily
Other Name: Placebo

Detailed Description:

There is solid scientific rational and preclinical data supporting a clinical trial of isradipine CR as a potential disease modifying agent in early PD. Human pharmacokinetic data demonstrate that it is feasible to achieve the serum concentrations in humans that were neuroprotective in preclinical models with the FDA approved dosage range. Pilot data demonstrate acceptable tolerability of isradipine CR in the PD population. Tolerability is inversely proportional to the dosage dependent. Considering that tolerability of isradipine CR is inversely proportional to the dosage exposure, it is essential to proceed with the dose selection tolerability study in preparation for the future efficacy trials.

The tolerability, defined as the ability to complete the study, of three dosages of isradipine CR relative to placebo in subjects with early Parkinson's disease will be examined first. The dosage that is tolerable and demonstrates preliminary efficacy will be evaluated further in the future pivotal efficacy studies.

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with early idiopathic PD. If tremor is not present, subjects must have unilateral onset and persistent asymmetry of the symptoms.
  • Be over 30 years old at the time of diagnosis of PD.
  • Hoehn & Yahr stage is less than or equal to 2.5.
  • Currently not receiving dopaminergic therapy and not projected to require dopaminergic therapy for at least 6 months from enrollment.
  • Use of MAO-B inhibitors (rasagiline, selegiline), amantadine, or anticholinergics will be allowed. The dosage has to be stable for 3 months prior to baseline visit and throughout the duration of the study.

Exclusion Criteria:

  • Subjects with a diagnosis of an atypical Parkinsonism
  • Subjects unwilling or unable to give informed consent
  • Use of CoQ10 at a dosage >600mg daily or use of creatine >5 grams daily within the 60 days prior to randomization
  • Exposure to dopaminergic PD therapy within 60 days prior to enrollment or for 3 months or more at any point in the past
  • History of clinically significant orthostatic hypotension or presence of orthostatic hypotension at the screening visit defined as > 20 mmHg change in systolic BP and >10mm change in diastolic BP after 2 min of standing, or baseline BP <90/60
  • History of congestive heart failure
  • History of bradycardia defined as heart rate <55
  • Presence of 2nd or 3rd degree atrioventricular block or other significant ECG abnormalities that in the investigator's opinion would compromise participation in study
  • Clinically significant abnormalities in the Screening Visit laboratory studies or electrocardiogram.
  • Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study
  • Prior exposure to isradipine or other calcium channel blockers within 6 months of baseline
  • Subjects with history of hypertension treated with a maximum of 2 other antihypertensive agents will be allowed provided that the doses of concomitant anti HTN therapy can be reduced/adjusted during the study based on the BP readings in consultation with the subject's primary care physician or cardiologist.
  • Use of grapefruit juice, Ginkgo biloba, St. John's wart and/or ginseng will be prohibited during the study (as they interfere with the metabolism of isradipine).
  • Presence of cognitive dysfunction defined by a Mini Mental Status Exam ( MMSE) score < 26 at screening
  • Subjects with clinically significant depression as determined by a Beck Depression Inventory (BDI) score >15 at screening
  • History of exposure to typical or atypical antipsychotics or other dopamine blocking agents within 6 months prior to enrollment
  • Subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to enrollment
  • Lactating women or women of childbearing potential who are not surgically sterilized have to use a reliable measure of contraception and have a negative serum pregnancy test at screening
  • Participation in other investigational drug trials within 30 days prior to screening
  • History of brain surgery for PD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00909545

Locations
United States, California
Parkinson Institute
Sunnyvale, California, United States, 94805
United States, Connecticut
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510
United States, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
University of Miami
Miami, Florida, United States, 33136
University of South Flordia
Tampa, Florida, United States, 33606
United States, Georgia
Emory University School of Medicine
Atlanta, Georgia, United States, 30329
United States, Hawaii
Pacific Health Institute
Honolulu, Hawaii, United States, 96817
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Massachusetts
Boston University
Boston, Massachusetts, United States, 02118
United States, Michigan
Michigan State University
East Lansing, Michigan, United States, 48824
United States, Minnesota
Park Nicolet Clinic
Golden Valley, Minnesota, United States, 55427
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University
St. Louis, Missouri, United States, 63110
United States, New York
University of Rochester
Rochester, New York, United States, 14618
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45219
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
University of Tennessee
Memphis, Tennessee, United States, 38104
Canada, Ontario
Ottowa Hospital Civic Site
Ottawa, Ontario, Canada, K1Y 4E9
Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8
Sponsors and Collaborators
Northwestern University
Michael J. Fox Foundation for Parkinson's Research
Northwestern University Dixon Fund
The Parkinson Study Group
Investigators
Study Chair: Tanya Simuni, MS Northwestern University
  More Information

Publications:

Responsible Party: Tanya Simuni, Prinicpal Investigator, Northwestern University
ClinicalTrials.gov Identifier: NCT00909545     History of Changes
Other Study ID Numbers: CTCC Protocol #124
Study First Received: May 26, 2009
Results First Received: October 2, 2012
Last Updated: April 16, 2013
Health Authority: United States: Institutional Review Board
Canada: Health Canada

Keywords provided by Northwestern University:
Early Parkinson disease

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Isradipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Vasodilator Agents
Antihypertensive Agents

ClinicalTrials.gov processed this record on July 28, 2014